Posting of Annual Report & Notice of AGM
12 September 2024
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces that the Annual Report and Accounts
for the year ended 31 March 2024 and the Notice of the Company's Annual
General Meeting (“AGM”) is being posted to shareholders today.
A copy of the 2024 Annual Report and Accounts, the Notice of AGM and
accompanying form of proxy will shortly be available to download from
the Company website here: https://www.fusionantibodies-ir.com/.
The AGM will be held on Tuesday, 8 October 2024 at 11.00am at the offices
of Fusion Antibodies, 1 Springbank Road, Springbank Industrial Estate,
Belfast BT17 0QL
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Adrian Kinkaid, Chief Executive
Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR | |
| Fusion Antibodies interactive investor hub | https://investorhub.fusionantibodies.com/ |
|
| Allenby Capital Limited | Tel: +44 (0) 20 3328 5656 | |
| James Reeve/Vivek Bhardwaj (Corporate
Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
||
| Shard Capital Partners LLP | ||
| Damon Heath (Joint Broker) | Tel: +44 (0) 207 186 9952 | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the development
of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression, antibody production,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies provides a broad range of services in antibody
generation, development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.
